

Comparative Study of Different Brands of Alprazolam

Dr. Safila Naveed¹ and Fatima Qamar²

¹ Jinnah University for women Karachi

Received: 11 December 2013 Accepted: 4 January 2014 Published: 15 January 2014

Abstract

Benzodiazepenes are the most widely used anxiolytic drug. They have largely replaced barbiturates and meprobamate in the treatment of Anxiety because they are safer and more effective. Alprazolam belongs to this class of drugs, it is used for the treatment of the anxiety symptoms of panic disorders. Present study deals with a brief overview of the comparative study of different brands of Alprazolam tablets according to Pharmacopeia (BP) United States Pharmacopeia (USP) . for this reason. 3 different brands of Alprazolam 0.5 mg tablets have been evaluated using quality control test of thickness, hardness, weight variation and friability to assess that whether these 3 brands are pharmaceutically equivalent.

Index terms— thickness, hardness, weight variation and friability, alprazolam.

1 Introduction

Alprazolam is a triazolobenzodiazepine. It is used in anxiety states and panic disorders [1,2]. Benzodiazepines are commonly used for deliberate self poisoning. It has been observed that in approximately one third of cases of deliberate self poisoning benzodiazepines are being used [3]. Alprazolam is a newer benzodiazepine and is used more commonly in overdose and no previous series of alprazolam poisonings were found. 14 case reports have been published including 5 reported deaths, 2 in which alprazolam was ingested alone [4]. According to reports published by American Association of Poison Control Centers National Data Collection System indicated that alprazolam was involved in thirty four fatal deliberate self poisonings over ten years 1992-2001 compared with thirty fatal deliberate self poisonings involving diazepam [5]. This reveals significant alprazolam toxicity if prescribing practices in the United States (US) mirror Australian trends where diazepam is prescribed at five to ten times the rate of alprazolam. A British study showed the fatal toxicity index (deaths per million prescriptions) for diazepam was 4.0 compared with 5.9 for alprazolam. [6]. These data suggest that alprazolam is more toxic in overdose than other benzodiazepines.

In human liver this drug is metabolized by CYP3A enzymes to hydroxylated metabolites . 4-hydroxy alprazolam (4-OHALP) is the major and less active metabolite while 7-Hydroxy alprazolam (7-OHALP) is the Author ??: Faculty of Pharmacy Jinnah University for women Karachi. e-mails: safila117@yahoo.com, fatima-mudassar2009@hotmail.com minor and active metabolite. There is an intrinsic difference in the biotransformation of alprazolam in liver and brain. As P450 enzymes present in brain is one-10th to one-15th of liver [7] II. The official range of hardness stated in BP/USP is not less than 4.00 Kg of pressure is required to break a tablet, so all of the samples were tested for hardness.

2 d) Friability

To evaluate how well the tablets stand up to coating, packing, shipping and other processing friability test were conducted. From each brand of legal and illegal products, 20 tablets were taken and de dusted before weighing, after weighing the tablet were placed in drum of friability tester of which each tablet rotated 100 times. Finally 20 tablets of each brand were de dusted and reweighed and their percentage losses of weight were calculated. According to BP & USP the total weight loss should not be more than one percent and no tablet should show any type of break or crack.

6 C) HARDNESS

44 Thickness Test: Thickness of above mentioned tablets including average , standard deviation, upper and lower
45 limits are in accordance with BP/USP III.

46 3 Results

47 Weight Variation Test: Wt. variation test of alprazolam tablets proved statistically that all the tablets were in
48 accordance to the BP/USP requirements. (Table ??

49 4 Discussion

50 Uniformity of weight is compendia standard while hardness and friability are non compendia standards to assess
51 the quality of the tablet. Friability is now included in USP.

52 5 a) Weight Variation

53 The table 1-3 indicate that weight variation values of Neuxam , Alp , Nerven showed that among three brands Alp
54 has the highest value of the mean as compared to other brands. The requirements are met with weight variation
55 according to USP that is ,weight of not more than two tablets out of all brands differs from the average weight
56 by more than 7.5% b) Friability

57 The table 3 and figure ??(%weight loss for Nexaum , Alp , Nerven) showed that the Nexaum has the highest
58 % weight lost and Alp has the lowest % weight lost when compared to Nerven.

59 All the three brands have less than 1% of weight lost which showed that these brands met the USP requirement.

60 6 c) Hardness

61 The official range of hardness stated in BP/USP is not less than 4.00 Kg of pressure is required to break a tablet,
62 so all of the samples were tested for hardness.

63 The table and figure showed that Nerven has the highest hardness value and Alp has showed lowest hardness
64 value. It shows that Alp showed to meet the USP requirement while the other two brands are beyond the USP
limit.



Figure 1:




Figure 2: A

A

Dosage form	Average weight	Percentage deviation
Uncoated and film coated tablets	80 mg or less More than 80 mg but less than 250 mg 250 mg or more	10 7.5 5
c) Hardness		

Figure 3: Table A :

1

Tablets	Different Brands		
	Neuxam	Alp	Nervin
1	179	195	165
2	173	199	158
3	180	200	150
4	178	200	156
5	180	202	159
6	190	200	156
7	190	203	151
8	178	205	156
9	179	198	160
10	176	205	154
11	173	200	160
12	176	195	158
13	180	199	151
14	177	203	156
15	173	198	150

Figure 4: Table 1 :

2

Tablets	Average (Gm)	Standard deviation	Upper limit (X+3S)	Lower limit (X-3S)
Neuxam	0.17985	0.005687	0.196911	0.162789
Alp	0.20025	0.002712	0.2083	0.19211
Nervin	0.15665	0.004308	0.16957	0.1437

Tablets	Result (Gm)	Table 3 : Weight Variation Test BP/USP Specification	Deviation from BP/USP Specification
Neuxam	0.17985		
Alp Nervin	0.20025 0.15665	Deviation should be $\pm 7.5\%$	Within specified limit

Figure 5: Table 2 :

4

Tablets Neuxam Alp		Nervin	
1	3.3	3.2	3.2
2	3.4	3.1	3.2
3	3.3	3.2	3.2
4	3.2	3.1	3.2
5	3.5	3.1	3.1
6	3.3	3.1	3.1
7	3.3	3.1	3.1
8	3.5	3.1	3.1
9	3.4	3.1	3.1
10	3.3	3.1	3.1

Figure 6: Table 4 :

5

Tablets	Average Thickness mm	Standard deviation	Upper limit (X+3S)	Lower limit (X-3S)
Neuxam	3.35	0.09	3.64	3.05
Alp	3.12	0.04	3.246	2.99
Nervin	3.14	0.05	3.29	2.98

Figure 7: Table 5 :

6

											Year 2014		
											27		
											Volume XIV Issue III		
											Version I		
											(B)		
											Medical Research		
											Global Journal of		
Tablets Neuxam					Alp			Nervin					
1	2	3	4	5	7.69	5.05	6.14	2.19	2.5	2.47	12.2	12.0	11.7
6	7				7.40	7.88	7.306	2.41	2.21	2.05	15.2	12.1	10.2
					7.16			1.92			13.2		
8					7.73			2.73			14.9		
9					7.60			2.45			13.2		
10					3.91			1.95			13.8		

[Note: © 2014 Global Journals Inc. (US)]

Figure 8: Table 6 :

7

Tablets	Average (Kg)	Standard deviation	Upper (X+3S)	limit	Lower limit (X-3S)
Neuxam	6.7866	1.335725	10.79377		2.779426
Alp	2.288	0.265949	3.085847		1.490153
Nervin	12.85	1.524795	17.42439		8.275615

Figure 9: Table 7 :

-
- 66 [Litovitz et al. ()] '1992 annual report of the American Association of Poison Control Centers Toxic Exposure
67 Surveillance System'. T L Litovitz , K C Holm , C Clancy , B F Schmitz , L R Clark , G M Oderda . *Am J*
68 *Emerg Med* 1993. 11 p. .
- 69 [Jonas and Cohon ()] 'A comparison of the safety and efficacy of alprazolam versus other agents in the treatment
70 of anxiety, panic, and depression: a review of the literature'. J M Jonas , M S Cohon . *J Clin Psychiatry*
71 1993. 54 p. . (Suppl)
- 72 [Abramowicz ()] 'Alprazolam for panic disorder'. M Abramowicz . *Med Lett Drugs Ther* 1991. 33 p. .
- 73 [Augenstein et al. ()] 'Captopril overdose resulting in hypotension'. W L Augenstein , K W Kulig , B H Rumack
74 . *JAMA* 1988. 259 p. .
- 75 [Pai et al. ()] 'Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacy-
76 ologically active metabolite. Pharmacogenomics'. H V Pai , S C Upadhya , S J Chinta , S N Hedge , V
77 Ravindranath . *J* 2002. 2 p. .
- 78 [Henderson et al. ()] 'Experience with 732 acute overdose patients admitted to an intensive care unit over six
79 years'. A Henderson , M Wright , S M Pond . *Med J Aust* 1993. 158 p. .
- 80 [Serfaty and Masterton ()] 'Fatal poisonings attributed to benzodiazepines in Britain during the 1980s'. M Serfaty
81 , G Masterton . *Br J Psychiatry* 1993. 163 p. .